Summary
Risk stratification and treatment decisions for leukaemia patients are regularly based on clinical markers determined at diagnosis, while measurements on system dynamics are often neglected. However, there is increasing evidence that linking quantitative time-course information to disease outcomes can improving the predictions for patient-specific treatment response.
We analyzed the potential of different computational methods to accurately predict relapse for chronic and acute myeloid leukaemia, particularly focusing on the influence of data quality and quantity. Technically, we used clinical reference data to generate in-silico patients with varying levels of data quality. Based hereon, we compared the performance of mechanistic models, generalized linear models, and neural networks with respect to their accuracy for relapse prediction. We found that data quality has a higher impact on prediction accuracy than the specific choice of the method. We further show that adapted treatment and measurement schemes can considerably improve prediction accuracy. Our proof-of-principle study highlights how computational methods and optimized data acquisition strategies can improve risk assessment and treatment of leukaemia patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Technische Universitaet Dresden, Faculty of Medicine Carl Gustav Carus, MeDDrive grant no. 60470 to NS.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
see original publications
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The patient data for the AML patients are published in [Hoffmann2020] and can be found here: https://doi.org/10.6084/m9.figshare.12871777.v1 The CML patient data will be provided upon request to the correspondent author (Ingmar Glauche). Source code is available at https://zenodo.org/record/4293490#.X8DznMtKg-Q